Is Medtronic (MDT) Undervalued After SPYRAL AFFIRM Results And FDA Label Update?

Simply Wall St.06:17

Medtronic (MDT) just reported new real world results from its SPYRAL AFFIRM study and secured an FDA label update for the Symplicity Spyral renal denervation system, which is sharpening investor focus...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681845101?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/company-cover/31348-card/1788955850933","is_english":true,"pubTime":"2026-11-08 06:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681845101","market":"sg","top_or_hot":-1,"title":"Is Medtronic (MDT) Undervalued After SPYRAL AFFIRM Results And FDA Label Update?","media":"Simply Wall St.","content":"<div>\n<p>Medtronic (MDT) just reported new real world results from its SPYRAL AFFIRM study and secured an FDA label update for the Symplicity Spyral renal denervation system, which is sharpening investor focus...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-mdt/medtronic/news/is-medtronic-mdt-undervalued-after-spyral-affirm-results-and\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Medtronic (MDT) Undervalued After SPYRAL AFFIRM Results And FDA Label Update?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Medtronic (MDT) Undervalued After SPYRAL AFFIRM Results And FDA Label Update?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-08 06:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-mdt/medtronic/news/is-medtronic-mdt-undervalued-after-spyral-affirm-results-and><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Medtronic (MDT) just reported new real world results from its SPYRAL AFFIRM study and secured an FDA label update for the Symplicity Spyral renal denervation system, which is sharpening investor focus...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-mdt/medtronic/news/is-medtronic-mdt-undervalued-after-spyral-affirm-results-and\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1061106388.HKD","symbol_name":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-mdt/medtronic/news/is-medtronic-mdt-undervalued-after-spyral-affirm-results-and","article_id":"2681845101","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/company-cover/31348-card/1788955850933"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-mdt/medtronic/news/is-medtronic-mdt-undervalued-after-spyral-affirm-results-and","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681845101","pubTimestamp":1794089840,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BBailey PembertonNovember 7, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","MDT":"美敦力","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU1236620750.USD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (USD) INC","BK4566":"资本集团","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU1236620834.HKD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (HKD) INC","BK4082":"医疗保健设备","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","BK4588":"碎股","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LABU":"三倍做多标普生物-Direxion","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","BK4585":"ETF&股票定投概念","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC"},"translate_title":"螺旋确认结果和FDA标签更新后，美敦力（MDT）被低估了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDT":1.5,"LABU":1.5},"content_text":"Medtronic (MDT) just reported new real world results from its SPYRAL AFFIRM study and secured an FDA label update for the Symplicity Spyral renal denervation system, which is sharpening investor focus on its hypertension franchise. Those clinical wins landed as Medtronic’s share price has been rebuilding momentum, with a 30 day share price return of 19.1% and a 90 day gain of 16.8% off a last close of US$101.80. Over a longer stretch, total shareholder return of 14.1% over one year and 58.9% across three years suggests investors have already been rewarded. In that context, the recent SPYRAL AFFIRM data and FDA label change appear more like fresh fuel for an existing hypertension thesis than the start of a completely new story. Scan for other hypertension and cardiovascular device stocks showing similar real world catalysts and price momentum by running the curated 35 healthcare AI stocks alongside Medtronic in your research.\nMedtronic has already delivered strong multi year returns and a sharp recent rebound in the share price. The key question now is whether the valuation still leaves meaningful upside potential, or if most of the gain is already on the table. AdvertisementMost Popular Narrative: 11.8% Undervalued Medtronic is pegged with a fair value of $115.38 according to the most followed narrative, which sits above the recent $101.80 share price and frames the hypertension news against a broader re rating story.  The phrase \"inflection point\" or its equivalents have orbited Medtronic's transcript language for several quarters. This quarter, management moved to secure the claim. Martha's closing remarks to the analyst who asked whether the \"mid-single-digit revenue grower, high single-digit EPS\" characterization of Medtronic still holds: \"Clearly, we have aspirations for higher growth than we've done historically... we're not satisfied with that.\" The framing is not a promise of specific targets, Investor Day in December is where those will be disclosed, but it is the first time management has used analyst-facing language to explicitly distance the company from its own historical growth ceiling.  See why 12 investors see Medtronic as 12% undervalued. According to LunaRodas, who authored the narrative, that gap between price and fair value is anchored in a mix of execution and repositioning rather than a single product win. The write up points to 13.7% reported organic growth in fiscal Q1 2027, high growth pockets in Cardiac Ablation Solutions and Cranial and Spinal Technologies, and margin guidance that is edging higher even as management reinvests some of the upside. The same narrative also flags trade offs that matter for anyone thinking about valuation. Operating margin expansion has been guided at approximately 50 basis points instead of 60 basis points, tariff costs have shifted from a structural talking point to something more managed, and robotics in soft tissue surgery is being reframed as a portfolio with Hugo and the Cornerstone Sentire system rather than a one platform bet. All of that sits alongside a planned MiniMed separation that management expects to lift gross and operating margins for the remaining group. Against that backdrop, Simply Wall St data points to a fair value P/E ratio of 32x for Medtronic versus an actual multiple of 23.8x at the last close. It also indicates a DCF based future cash flow value estimate of $111.26 per share. The narrative fair value of $115.38 suggests a similar conclusion: that the current price embeds more modest expectations than those implied by that earnings and cash flow work. Result: Fair Value of $115.38 (UNDERVALUED) Still, if Medtronic stumbles on MiniMed separation timing or fails to sustain recent organic growth, that 11.8% undervaluation story could unravel quickly. Find out about the key risks to this Medtronic narrative. Next Steps That 11.8% undervalued narrative is only one way to read Medtronic. Act quickly, review the full breakdown, and weigh the 5 key rewards. Looking for more investment ideas beyond Medtronic? If you stop with Medtronic, you risk missing other opportunities that fit your style, so widen your search now using focused screeners built for investors like you.  Target stability first and cut portfolio stress by scanning a 29 resilient stocks with low risk scores that score well on resilience and lower risk profiles. Hunt for value gaps by reviewing a 39 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their strengths. Build a watchlist of future leaders by combing through a 19 high quality undiscovered gems with quality metrics that many investors are still overlooking.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681845101","isCrawlerRequest":true}